Novel Medications for Opiate Detoxification - 4
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Opioid-Related Disorders; Substance-Related Disorders
Intervention: Clonidine (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Thomas R Kosten, M.D., Principal Investigator, Affiliation: VA Connecticut Healthcare System
Summary
The purpose of this study is to evaluate novel medications for opiate detoxification.
Clinical Details
Official title: Novel Medications for Opiate Detoxification
Study design: Treatment
Primary outcome: Withdrawal severity
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Please contact site for information.
Locations and Contacts
VA Connecticut Healthcare System, New Haven, Connecticut 06519, United States
Additional Information
Last updated: June 23, 2005
|
